These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 2481789

  • 21. How useful are beta-blockers in cardiovascular disease?
    Bangalore S, Parkar S, Messerli FH.
    Anadolu Kardiyol Derg; 2006 Dec; 6(4):358-63. PubMed ID: 17162285
    [Abstract] [Full Text] [Related]

  • 22. [Beta-blockers and arterial hypertension. Evidence-based medicine or excessive perseverance?].
    Verdecchia P, Angeli F, Achilli P, Castellani C, Repaci S, Ambrosio G.
    G Ital Cardiol (Rome); 2007 Sep; 8(9):552-8. PubMed ID: 17972424
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Optimal medical management of peripheral arterial disease.
    Rice TW, Lumsden AB.
    Vasc Endovascular Surg; 2006 Sep; 40(4):312-27. PubMed ID: 16959725
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Current status of labetalol, the first alpha- and beta-blocking agent.
    Kanto JH.
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):617-28. PubMed ID: 2867049
    [Abstract] [Full Text] [Related]

  • 29. Are we misunderstanding beta-blockers.
    Cruickshank JM.
    Int J Cardiol; 2007 Aug 09; 120(1):10-27. PubMed ID: 17433471
    [Abstract] [Full Text] [Related]

  • 30. Hypertension with concomitant conditions: the changing role of beta-adrenoceptor blockade.
    Weber MA.
    Am Heart J; 1991 Feb 09; 121(2 Pt 2):716-23. PubMed ID: 1671191
    [Abstract] [Full Text] [Related]

  • 31. Adverse reactions with beta-adrenoceptor blocking drugs. An update.
    Lewis RV, Lofthouse C.
    Drug Saf; 1993 Oct 09; 9(4):272-9. PubMed ID: 7903148
    [Abstract] [Full Text] [Related]

  • 32. Required beta blocker profile in the elderly.
    Opie LH.
    Cardiovasc Drugs Ther; 1991 Jan 09; 4 Suppl 6():1273-80. PubMed ID: 1672603
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Do we need more beta-blockers?
    Cruickshank JM, Lund-Johansen P.
    Blood Press Suppl; 1992 Jan 09; 1():58-9. PubMed ID: 1364182
    [No Abstract] [Full Text] [Related]

  • 35. The therapeutic potential of third-generation beta-adrenergic receptor blockers. Satellite symposium to the Xth Congress of the European Society of Cardiology. Vienna, Austria, August 31, 1988.
    J Cardiovasc Pharmacol; 1989 Jan 09; 14 Suppl 7():S1-44. PubMed ID: 2481784
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Celiprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cardiovascular disease.
    Milne RJ, Buckley MM.
    Drugs; 1991 Jun 09; 41(6):941-69. PubMed ID: 1715268
    [Abstract] [Full Text] [Related]

  • 38. Newer beta blockers and the treatment of hypertension.
    McAreavey D, Vermeulen R, Robertson JI.
    Cardiovasc Drugs Ther; 1991 Jun 09; 5(3):577-87. PubMed ID: 1678961
    [Abstract] [Full Text] [Related]

  • 39. Pharmacology of third-generation beta-blockers: greater benefits, fewer risks.
    Kendall MJ.
    J Cardiovasc Pharmacol; 1989 Jun 09; 14 Suppl 7():S4-8. PubMed ID: 2481789
    [Abstract] [Full Text] [Related]

  • 40. Do we need a new classification of beta-blockers?
    Kendall MJ.
    J Hum Hypertens; 1990 Jun 09; 4 Suppl 2():27-9. PubMed ID: 1973460
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.